Viracta Therapeutics Inc
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trial… Read more
Viracta Therapeutics Inc (VIRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 1.072x
Based on the latest financial reports, Viracta Therapeutics Inc (VIRX) has a cash flow conversion efficiency ratio of 1.072x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.09 Million) by net assets ($-6.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Viracta Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2005–2023)
This chart illustrates how Viracta Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Viracta Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viracta Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BANCA GENERALI
BE:B7A
|
N/A |
|
Environmental Waste International Inc
PINK:YEWTF
|
0.130x |
|
The Hydration Pharmaceuticals Company Ltd
AU:HPC
|
-0.606x |
|
BAAPL
PINK:BAAPL
|
N/A |
|
Xigem Technologies Corporation
PINK:XIGMF
|
0.627x |
|
OCI COMPANY (NEW)
KQ:456040
|
N/A |
|
PROTON MOT.PWR S.LS-005
F:P6K0
|
N/A |
|
Golden Spike Resources Corp.
PINK:GSPRF
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Viracta Therapeutics Inc (2005–2023)
The table below shows the annual cash flow conversion efficiency of Viracta Therapeutics Inc from 2005 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $18.32 Million | $-39.89 Million | -2.178x | -275.27% |
| 2022-12-31 | $61.10 Million | $-35.46 Million | -0.580x | -190.50% |
| 2021-12-31 | $94.37 Million | $-18.85 Million | -0.200x | -157.49% |
| 2020-12-31 | $-46.20 Million | $-16.05 Million | 0.347x | +143.14% |
| 2019-12-31 | $27.54 Million | $-22.18 Million | -0.805x | +86.82% |
| 2018-12-31 | $3.99 Million | $-24.40 Million | -6.112x | -264.31% |
| 2017-12-31 | $21.54 Million | $-36.14 Million | -1.678x | +4.58% |
| 2016-12-31 | $21.02 Million | $-36.96 Million | -1.758x | -24.34% |
| 2015-12-31 | $27.39 Million | $-38.73 Million | -1.414x | +54.81% |
| 2014-12-31 | $13.80 Million | $-43.18 Million | -3.129x | -151.70% |
| 2013-12-31 | $-6.18 Million | $-37.42 Million | 6.052x | +779.94% |
| 2012-12-31 | $11.96 Million | $-10.64 Million | -0.890x | -9.21% |
| 2011-12-31 | $28.02 Million | $-22.84 Million | -0.815x | -77.67% |
| 2010-12-31 | $42.25 Million | $-19.38 Million | -0.459x | +95.32% |
| 2009-12-31 | $2.06 Million | $-20.18 Million | -9.796x | -79.31% |
| 2008-12-31 | $6.49 Million | $-35.46 Million | -5.463x | -556.31% |
| 2007-12-31 | $41.39 Million | $-34.46 Million | -0.832x | -74.57% |
| 2006-12-31 | $56.80 Million | $-27.08 Million | -0.477x | +12.44% |
| 2005-12-31 | $38.47 Million | $-20.95 Million | -0.545x | -- |